Clinical TrialAnimal StudyHighlightedRandomized, crossover clinical efficacy trial in humans and mice on tear secretion promotion and lacrimal gland protection by molecular hydrogenMHID-8498103PMID: 337420602021Scientific ReportsMiyuki Kubota, Motoko Kawashima, Sachiko Inoue, Toshihiro Imada, Shigeru Nakamura, Shunsuke Kubota, et al.The incidence of dry eye disease is increasing worldwide because of the aging population and increasing use of information technology. Dry eye disease manifests as tear-layer instability and inflammation caused by osmotic hypersensitization in tear fluids; however, to our knowledge, no agent that treats both pathologies simultaneously is available. Molecular hydrogen (H2) is known to be effective
Literature ReviewHydrogen gas: from clinical medicine to an emerging ergogenic molecule for sports athletesMHID-3461972PMID: 309702152019Canadian Journal of Physiology and PharmacologyTyler W. LeBaron, Ismail Laher, Branislav Kura, Jan SlezakH2 has been clinically demonstrated to provide antioxidant and anti-inflammatory effects, which makes it an attractive agent in exercise medicine. Although exercise provides a multiplicity of benefits including decreased risk of disease, it can also have detrimental effects. For example, chronic high-intensity exercise in elite athletes, or sporadic bouts of exercise (i.e. noxious exercise) in unt
